Efficacia e tollerabilità di Zonisamide (Zonegran™) in pazienti con ULD: Studio pilota open-label

Translated title of the contribution: Efficacy and tolerability of Zonisamide (Zonegran™) in ULD: A pilot open-label trial

M. Pezzella, D. Italiano, A. Coppola, G. Giudizioso, L. Santulli, C. Ciampa, A. Magaudda, E. Ferlazzo, S. Striano, P. Striano

Research output: Contribution to journalArticle

Abstract

Unverricht-Lundborg disease (EPM1) is the most common form of progressive myoclonus epilepsy. Symptoms stabilize in adulthood but chronic myoclonus frequently remains the primary cause of disability. We carried out a pragmatic, pilot, open-label trial to evaluate the tolerability and the antimyoclonic efficacy of Zonisamide (ZNS) in 12 patients with EPM1. The ZNS target dose was 300-500 mg/day. ZNS add-on was associated with clinical improvement of myoclonus and lowering of mean scores on all Unified Myoclonus Rating Scale (UMRS) sections except section 6 (physician's assessment of disability). ZNS was generally well tolerated and only two patients withdrew during follow-up phase due to mild adverse effects.

Translated title of the contributionEfficacy and tolerability of Zonisamide (Zonegran™) in ULD: A pilot open-label trial
Original languageItalian
Pages (from-to)81-82
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number142
Publication statusPublished - Apr 2011

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Efficacy and tolerability of Zonisamide (Zonegran™) in ULD: A pilot open-label trial'. Together they form a unique fingerprint.

  • Cite this

    Pezzella, M., Italiano, D., Coppola, A., Giudizioso, G., Santulli, L., Ciampa, C., Magaudda, A., Ferlazzo, E., Striano, S., & Striano, P. (2011). Efficacia e tollerabilità di Zonisamide (Zonegran™) in pazienti con ULD: Studio pilota open-label. Bollettino - Lega Italiana contro l'Epilessia, (142), 81-82.